ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Options for parenteral venous thromboembolism (VTE) prophylaxis in patients with cancer

Options for parenteral venous thromboembolism (VTE) prophylaxis in patients with cancer
  Hospitalized medical patients Surgical patients (postoperative dosing*)
Unfractionated heparin
Unfractionated heparin 5000 units once every 8 to 12 hours 5000 units once every 8 to 12 hours beginning 6 to 24 hours postoperatively
Low molecular weight (LMW) heparin
Dalteparin 5000 units once daily 5000 units once daily beginning 12 to 24 hours postoperatively
Enoxaparin 40 mg once daily 40 mg once daily beginning 12 to 24 hours postoperatively
Nadroparin 3800 anti-Xa units once daily 3800 anti-Xa units once daily beginning 12 to 24 hours postoperatively
Tinzaparin

3500 anti-Xa units once daily

3500 anti-Xa units once daily beginning 12 to 24 hours postoperatively
Fondaparinux
Fondaparinux 2.5 mg once daily

2.5 mg once daily beginning 6 to 8 hours postoperatively or beginning on the morning of the day after surgery

These doses apply to VTE prophylaxis (not treatment) and are appropriate for patients with active cancer. Administration is by subcutaneous injection for all of the agents listed. Dose adjustments may be required for renal insufficiency or for obesity. For surgical patients, some surgeons will start prophylaxis preoperatively, depending on the specific procedure, bleeding risk, and thrombosis risk. Refer to UpToDate topics on VTE prevention in patients with cancer and VTE treatment in patients with cancer for further information including use of parenteral as well as oral anticoagulants.
VTE: venous thromboembolism.
* Preoperative dosing may be appropriate in selected settings as long as there is no concern about bleeding with anticoagulation (eg, due to neuraxial anesthesia or spine surgery). Refer to UpToDate for details of anticoagulation management in individuals undergoing neuraxial anesthesia or procedures involving the central nervous system.
¶ Not available in the United States.
Adapted from: Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31:2189.
Graphic 119688 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟